Climb for a Cause: Supporting Research Cancer

In February 2026, Brad Watts will join biotech leaders on a once-in-a-lifetime climb to summit Mt. Kilimanjaro (19,340 ft / 5,895 m) as part of the Timmerman Traverse In 2025 alone, the Traverse raised $1.15M from 1,000+ donors, since 2021 $14M total since 2017 across all causes. This year, the team is raising $1M for the Damon Runyon Cancer Research Foundation, which funds early-career scientists pursuing high-risk, high-reward cancer research.

Why Brad is Doing the Climb?
Diagnosed in 2017 with two forms of aggressive Non-Hodgkin’s Lymphoma at age 29, Brad underwent years of treatment—including chemotherapy, radiation, a stem cell transplant, CAR-T therapy, and immunotherapy—and is now in remission, enjoying life with his wife Shea and their two young sons. As a survivor, patient advocate, and biotech consultant, he has seen firsthand how research transforms lives, and this climb is his way of helping fuel the next breakthroughs and give patients more time.